Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Programmable Medicine Operating Company is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and are distributed across 2 distinct art units. This distribution suggests a broader technical or procedural scope than portfolios confined to a single unit. By operating in 2 distinct art units, the company must navigate the specific cultures and requirements of two different administrative groups.
Jake Minh Vu is the busiest examiner for this portfolio, with 1 pending office action assigned. Since there are 2 distinct examiners for 2 pending actions, each examiner is responsible for exactly one half of the company's current pending workload. This one to one ratio between examiners and actions means the company's success is equally dependent on two different individuals. The involvement of 2 distinct art units further diversifies the prosecution environment, requiring a strategy that accounts for different technical standards across the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, JAKE MINH | 1 | 41.0% | +27.0% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034551 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | VU, JAKE MINH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | PIHONAK, SARAH | 22d |
| 18034551 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | VU, JAKE MINH | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034551 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | VU, JAKE MINH | 1618 | §102§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18016262 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY | PIHONAK, SARAH | 1627 | §103 | Final Rejection | 22d | Pending | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProgrammable Medicine Operating Company has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jake Minh Vu has the most, with 1 of Programmable Medicine Operating Company's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
